title: Antineoplastic agent workplace contamination study: the Alberta Cancer Board Pharmacy perspective.
abstract: OBJECTIVE
  To investigate the feasibility of routine monitoring for workplace antineoplastic agent contamination in the Alberta Cancer Board (ACB) pharmacy practice environment.
  
  
  METHODS
  The ACB in the Canadian province of Alberta, which includes two public tertiary centres and 17 associated community satellite sites based around the province in existing hospitals.
  
  
  METHODS
  Obtained organizational support and input prior to launching the feasibility study (Phase I). Samples were analysed for a common cytotoxic agent - cyclophosphamide. Surfaces chosen were within the biological safety cabinets, workplace counter tops and on external surfaces of vials provided by manufacturers. Blank samples and known contaminated controls were included in Phase I to reconfirm the methodology in a previously published study. Feasibility aspects of logistics and financial expenses were examined. A second phase (Phase II) was completed to test other areas of the pharmacy and vials, with blank samples included to reconfirm previously mentioned methodology.
  
  
  RESULTS
  The results determined that the samples tested were below acceptable detection limits with the exception of the known contaminated sample (Phase I) and exterior surfaces of vials (Phase II).
  
  
  CONCLUSIONS
  This project has increased staff awareness of the sources for antineoplastic agent workplace contamination. Some practice changes were instituted during the project itself. Logistics and expenses were realistic for routine monitoring to be adopted.
authors.affiliation: Cross Cancer Institute Site, Edmonton, Alberta, Canada. heidis@cancerboard.ab.ca
authors.forename: Heidi
authors.initials: H
authors.lastname: Schulz
authors.forename: Susan
authors.initials: S
authors.lastname: Bigelow
authors.forename: Roxanne
authors.initials: R
authors.lastname: Dobish
authors.forename: Carole R
authors.initials: CR
authors.lastname: Chambers
mesh_terms: D000416:Alberta; D000970:Antineoplastic Agents / Q000032:analysis*; D002173:Cancer Care Facilities; D003520:Cyclophosphamide / Q000032:analysis*; D004349:Drug Packaging; D004784:Environmental Monitoring / Q000379:methods* / Q000592:standards; D005240:Feasibility Studies; D017575:Gloves, Protective / Q000592:standards; D006801:Humans; D016273:Occupational Exposure / Q000032:analysis* / Q000517:prevention & control; D010594:Pharmacies / Q000592:standards*; D010604:Pharmacy / Q000592:standards*; D010607:Pharmacy Service, Hospital; D017751:Safety Management
chemical_list: D000970:Antineoplastic Agents; D003520:Cyclophosphamide